Panacea Biotec's Q1 FY25 Financials Show Mixed Results, Investors Urged to Analyze Indicators.

Operating Profit Margin – Quarterly: Lowest at -1.10% in the last five quarters. Company’s profitability has been impacted due to higher expenses.

Inventory Turnover Ratio – Half Yearly: Lowest at 2.28 times in the last five half yearly periods. Company’s inventory management needs improvement.

Despite the mixed financial performance, MarketsMOJO has given a ‘Strong Sell’ call for Panacea Biotec’s stock. This could be due to the company’s declining score and negative trends in certain financial indicators.

However, there are some positive aspects to the company’s financials. The Profit After Tax (PAT) has shown consistent growth in the last five quarters and the Net Sales have also increased by 23.12% year on year. The Debtors Turnover Ratio has also improved, indicating that the company has been able to collect payments from its debtors faster.

On the other hand, the company’s Cash and Cash Equivalents have decreased in the last six half yearly periods, indicating a deteriorating short term liquidity. The Operating Profit Margin has also been impacted due to higher expenses and the Inventory Turnover Ratio needs improvement.

Overall, Panacea Biotec’s financial performance for the quarter ending March 2024 has been flat. Investors should carefully consider all the financial indicators before making any investment decisions.